Is abcc6 down regulated in vascular smooth muscle cells in vascular calcification?
Best insight from top research papers
Yes, ABCC6 is not directly mentioned in the provided contexts. However, the contexts discuss the downregulation of other genes and proteins in vascular smooth muscle cells (VSMCs) related to vascular calcification. SIRT6 is downregulated in VSMCs during vascular calcification , while Erythropoietin (EPO) promotes VSMC calcification by upregulating genes associated with bone formation like BMP2 and RUNX2 . Additionally, IL-6 induces calcification of human artery smooth muscle cells by upregulating BMP2 expression . Although ABCC6 is not specifically mentioned, the downregulation of SIRT6 and the upregulation of BMP2 and RUNX2 in VSMCs during vascular calcification suggest a complex interplay of gene regulation in this process.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Not addressed in the paper. | |
| Yes, the abstract does not mention the downregulation of abcc6 in vascular smooth muscle cells during vascular calcification. Therefore, this specific gene regulation is not addressed in the paper. | |
| Not addressed in the paper. | |
34 Citations | Not addressed in the paper. |
| Yes, the paper does not specifically mention the downregulation of abcc6 in vascular smooth muscle cells in vascular calcification. "Not addressed in the paper." |
Related Questions
How does wnt signaling pathway works in vascular calcification?4 answersThe Wnt signaling pathway plays a crucial role in vascular calcification by promoting the osteochondrogenic transition of vascular smooth muscle cells (VSMCs). This pathway involves the activation of β-catenin-dependent and -independent Wnt signals, leading to the upregulation of osteochondrogenic transcription factors like RUNX2 and SOX9. Additionally, the Wnt pathway can be antagonized by PPARγ activation, which inhibits Wnt signaling through the expression of WNT inhibitors and direct interaction with β-catenin. Studies have shown that in chronic kidney disease (CKD), there is enhanced Wnt signaling in vascular tissues, correlating with increased vascular calcification and blood pressure variability. Furthermore, SIRT1, a protein deacetylase, may modulate the canonical Wnt signaling pathways, influencing the activation of osteogenic factors and contributing to the progression of calcification.
Does IL-6 have anti-angiogenic effects?5 answersIL-6 has conflicting effects on angiogenesis. While some studies suggest that IL-6 can enhance angiogenesis, others indicate that IL-6 can inhibit angiogenesis. In patients with advanced colorectal cancer, high levels of IL-6 were associated with lower treatment efficiency in patients treated with chemotherapy alone, but not in patients treated with bevacizumab. IL-6 trans-signaling was found to inhibit the migration, proliferation, and tube formation ability of endothelial cells, suggesting an anti-angiogenic effect. Additionally, IL-6 trans-signaling upregulated anti-angiogenic factors and downregulated pro-angiogenic factors in endothelial cells. Furthermore, IL-6 was shown to be necessary and sufficient for choroidal angiogenesis, and targeting IL-6 or the IL-6 receptor could be an effective therapy for neovascular age-related macular degeneration. Overall, the role of IL-6 in angiogenesis appears to be complex, with both pro-angiogenic and anti-angiogenic effects depending on the context.
What is the effect of PFKFB3 upregulation on calcific aortic valve disease?5 answersPFKFB3 upregulation has been shown to have a significant effect on calcific aortic valve disease (CAVD). In CAVD, the expression of PFKFB3, a master activator of glycolysis, is increased in cardiac fibroblasts and vascular smooth muscle cells (VSMCs). This upregulation of PFKFB3 promotes the osteogenic transition of valve interstitial cells (VICs) and VSMCs, leading to the mineralization of the aortic valve (AV) and vascular calcification. Inhibition of PFKFB3 has been shown to alleviate post-myocardial infarction (MI) cardiac fibrosis and attenuate cardiac fibrosis in post-MI mice. Additionally, κ-opioid receptor activation has been found to inhibit VSMC calcification by reducing PFKFB3 expression and lactate content, providing a potential drug target for the treatment of vascular calcification. These findings highlight the importance of PFKFB3 upregulation in the pathogenesis of CAVD and suggest that targeting PFKFB3 could be a therapeutic strategy for mitigating the progression of CAVD.
Is CD63 involved in vascular calcification?4 answersCD63 involvement in vascular calcification is not mentioned in any of the provided abstracts.
Downregulation of IL-1Ra on vascular calcification5 answersDownregulation of IL-1Ra has been observed in ESCC tissues and cells and is strongly correlated with pathological stage and lymphatic metastasis. IL-1β, a proinflammatory cytokine, plays a role in the pathogenesis of atherosclerotic vascular calcification. Inflammatory cytokines such as IL-1β have been shown to stimulate the expression of tissue-non specific alkaline phosphatase (TNAP), a key enzyme in the mineralization process, and trigger the trans-differentiation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells. However, the inhibitory effects of inflammatory cytokines on bone formation are known. The mechanism underlying the effect of anti-IL-1β therapy on reducing the incidence of cardiovascular events by affecting atherosclerotic vascular calcification remains unclear.
How does calcification of blood vessels affect the heart?5 answersCalcification of blood vessels can have a significant impact on the heart. Vascular calcification, which occurs in arteries and heart valves, can impair vascular resistance, leading to heart failure. It can also increase the risk of atherosclerotic plaque rupture, contributing to heart attacks and strokes. Calcification of the aortic valve can result in narrowing of the valve opening, reducing blood flow and potentially causing heart failure. The mechanisms driving vascular and valvular calcification are not fully understood, but they are believed to involve distinct disease-driving mechanisms. Currently, there are no approved drug therapies to prevent or regress cardiovascular calcification. Understanding the molecular and biological processes involved in calcification is crucial for developing effective treatments.